Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-CAR011 in Refractory DLBCL
NCT02976857Phase 1Completed
- Sponsor
- AbelZeta
- Start
- Dec 2016
- Primary completion
- Sep 2018
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of C-CAR011 in diffuse large B-cell lymphoma (DLBCL), sponsored by AbelZeta. Primary endpoint: Dose-limiting toxicity at 28 days. Started Dec 2016; status: completed.
02
Drugs
C-CAR011
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02976857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02976857.